Business
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025.
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Full year revenue growth of 97% driven by strong performance in molecular profiling services","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025.","length":274,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MqHe21QS1MqglPOGiTFaYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fourth Quarter 2025 Financial Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $292.9 million, an increase of 125% over the corresponding prior year period.","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% over the corresponding prior year period, and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.","length":239,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported gross margin of 75%, an approximate 2,000 bps improvement over the corresponding prior year period.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported net income of $82.0 million.","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported positive Adjusted EBITDA of $106.1 million.","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported positive net cash provid...